CHICAGO, July 14 — Glioblastoma remains one of the most formidable diagnoses in medicine. It’s the most common and aggressive malignant brain tumor in adults, accounting for roughly 15% of all primary brain tumors. For patients and their families, the numbers are sobering: the median survival time with standard treatment hovers around 12 to 15 months.
That standard treatment is a three-pronged approach. Surgeons remove as much of the tumor as safely possible, a procedure called surgical resection.
That’s followed by radiation therapy and chemotherapy with a drug called temozolomide.
The Grim Statistics
The five-year survival rate for glioblastoma is less than 5%. That means fewer than one in 20 patients live five years past their diagnosis. It’s a stark reality that drives researchers to keep pushing.
Some patients do beat the odds. Theo Burrell, for instance, has survived longer than the typical 12-to-15-month window.
Stories like Burrell’s offer a glimpse of hope, but they remain exceptions rather than the rule. The exact cause of glioblastoma remains unknown. That’s a frustrating blank spot on the map for researchers.
What doctors do know is that certain factors raise the risk: exposure to ionizing radiation, such as from past radiation therapy for other cancers, and certain genetic syndromes.
Where Research Is Headed
The search for better treatments is relentless. Two approaches stand out in current research. One is tumor treating fields, or TTFields.
This therapy uses low-intensity electric fields to disrupt cancer cell division. Patients wear a device on their scalp that generates these fields.
The other major avenue is immunotherapy. This approach tries to train the patient’s own immune system to recognize and attack glioblastoma cells. The practical upshot for patients right now is that the standard three-pronged treatment remains the backbone of care.
TTFields are available as an additional option for some patients, and immunotherapy is still largely in the clinical trial phase.
What Comes Next
The next few years will be critical. Researchers are testing combinations of existing treatments with new drugs, trying to find a cocktail that can push that five-year survival rate higher. They’re also studying the genetics of glioblastoma tumors more closely, hoping to find vulnerabilities that can be targeted with precision drugs.
For now, the message from the medical community is clear: early detection and aggressive treatment offer the best chance, but the fight is far from over. Consult your doctor for medical advice.
